Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
NewAmsterdam Pharma Company ( (NAMS) ) has provided an announcement.
On June 9, 2025, NewAmsterdam Pharma announced positive topline data from their Phase 3 BROADWAY clinical trial, which evaluated the effects of obicetrapib on Alzheimer’s Disease biomarkers. The study showed statistically significant reductions in the primary outcome measure of p-tau217 in both the full study population and ApoE4 carriers, suggesting a potential preventive strategy for Alzheimer’s Disease. These findings highlight the potential of CETP inhibition in mitigating Alzheimer’s risk and further differentiate obicetrapib as a uniquely effective therapy addressing multiple health concerns, including cardiovascular and neurodegenerative diseases.
The most recent analyst rating on (NAMS) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
The overall stock score of 56 reflects mixed financial performance with growth potential overshadowed by current profitability challenges. Technical analysis shows a neutral trend, while the valuation remains strained due to lack of profitability. Positive corporate events, including promising trial results and strategic board appointments, are significant factors supporting the score.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol. The company aims to provide safe, well-tolerated, and convenient LDL-lowering therapies for patients for whom existing treatments are not effective or well-tolerated.
Average Trading Volume: 916,407
Technical Sentiment Signal: Buy
Current Market Cap: $2.26B
For an in-depth examination of NAMS stock, go to TipRanks’ Stock Analysis page.